A real-world clinical experience on effectiveness of remogliflozin etabonate in management of Indian patients with T2DM

被引：0
|
作者：
Mahapatra, H. [1 ]
Dalai, S. [2 ]
Sahoo, A. [3 ]
Khuntia, M. [4 ]
机构：
[1] IMS & SUM Hosp, Dept Endocrinol, Sevayan Diabet Ctr, Bhubaneswar, India
[2] IMS & SUM Hosp, Dept Med, Bhubaneswar, India
[3] IMS & SUM Hosp, Dept Endocrinol, Bhubaneswar, India
[4] Sevayan Diabet Ctr, Dept Endocrinol, Bhubaneswar, India
来源：
DIABETES RESEARCH AND CLINICAL PRACTICE | 2022年 / 186卷
关键词：
D O I：
10.1016/j.diabres.2022.109511
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
IDF21-0310
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Remogliflozin in Indian T2DM Patients: A Real-World Study
    Bhattacharya, Supratik
    Katare, Sagar
    [J]. DIABETES, 2020, 69
  • [2] Real world assessment of effectiveness and safety of FDC of remogliflozin etabonate and Vildagliptin in T2DM patients
    Bhattacharyya, S.
    Katare, S.
    Khaladkar, K.
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 186
  • [3] Phase 3 Results of Fixed -Dose Combination of Remogliflozin Etabonate and Vildagliptin in Indian T2DM Patients
    Mohan, Brij
    Chawla, Manoj S.
    Kodgule, Rahul R.
    Tandon, Monika
    Katare, Sagar
    Suryawanshi, Sachin
    Barkate, Hanmant V.
    [J]. DIABETES, 2021, 70
  • [4] Real-world assessment of effectiveness and safety profile of remogliflozin etabonate in management of type 2 diabetes mellitus
    Bipin Sethi
    Subhankar Chowdhury
    Supratik Bhattacharya
    Sagar Katare
    Sachin Suryawanshi
    Hanmant Barkate
    [J]. International Journal of Diabetes in Developing Countries, 2023, 43 : 214 - 225
  • [5] Real-world assessment of effectiveness and safety profile of remogliflozin etabonate in management of type 2 diabetes mellitus
    Sethi, Bipin
    Chowdhury, Subhankar
    Bhattacharya, Supratik
    Katare, Sagar
    Suryawanshi, Sachin
    Barkate, Hanmant
    [J]. INTERNATIONAL JOURNAL OF DIABETES IN DEVELOPING COUNTRIES, 2023, 43 (02) : 214 - 225
  • [6] Clinical Effectiveness of Canagliflozin 100mg in T2DM Patients-A Real-World Study
    Chakravorty, Saibal, Sr.
    Patel, Vikas Kumar
    [J]. DIABETES, 2019, 68
  • [7] Real-World Effectiveness, Adherence, and Persistence among Patients with T2DM Initiating Dulaglutide
    Mody, Reema
    Grabner, Michael
    Yu, Maria
    Turner, Ralph
    Kwan, Anita
    York, Whitney
    Lando, Laura Fernandez
    [J]. DIABETES, 2017, 66 : A355 - A355
  • [8] Real-World Clinical Inertia amongst T2DM Patients: Clinical, Physician, and Patient Viewpoints
    Higgins, Victoria
    Leith, Andrea
    Kelly, Melissa
    Ellams, Amy
    [J]. DIABETES, 2017, 66 : A173 - A173
  • [9] Results of Randomized Double Blind Phase III trial of FDC of Remogliflozin Etabonate and Teneligliptin in T2DM patients
    Balamurgan, R.
    Mohan, B.
    Kodgule, R.
    Tandon, M.
    Pendse, A.
    Khaladkar, K.
    Sharath, R.
    Katare, S.
    Suryawanshi, S.
    Barkate, H.
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 186
  • [10] INTENSIFY: effectiveness of insulin degludec/liraglutide (IDegLira) in a real-world T2DM population in the UAE
    Al Awadi, F.
    Aly, H.
    Bashier, A.
    Benavente, J. Medina
    Dhanwal, D. Kumar
    Jallo, M.
    Singhal, S.
    Abusnana, S.
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 186
12345